GlaxoSmithKline (GSK) will present new data from key focus areas within its oncology portfolio at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the European Hematology Association (EHA) 2021 Virtual Congress (June 9-17).
The company will present new data on its approved therapies, BLENREP (belantamab mafodotin), JEMPERLI (dostarlimab) and ZEJULA (niraparib), as well as its investigational T-cell receptor therapy (TCR-T) letetresgene autoleucel (lete-cel; GSK3377794) for solid tumours.
Dr Axel Hoos, Senior Vice President and Head of Oncology R&D, GSK said: “The data we will share at ASCO and EHA demonstrate the continued strengthening of our oncology R&D pipeline in our focus areas of immuno-oncology, cell therapy and synthetic lethality. We are committed to ensuring our three approved medicines – niraparib, belantamab mafodotin and dostarlimab – help as many patients as possible while exploring novel approaches to expand treatment options for the millions of lives impacted by cancer each year.”
Additionally, GSK will present new data regarding the management of adverse events associated with belantamab mafodotin in relapsed/refractory multiple myeloma. It will also share data from combined analysis of three Phase III studies in patients with BRCA mutated ovarian cancer, examining the efficacy of niraparib, as well as its safety. This research adds to the understanding of the use of this poly (ADP-ribose) polymerase (PARP) inhibitor for maintenance treatment in ovarian cancer.
Image credit: Chris Montgomery
